Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We expect  Perrigo Company (PRGO - Analyst Report) to beat expectations when it releases its second quarter fiscal 2013 results before the opening bell on Feb 1, 2013. The company’s fiscal year ends on the last Saturday of June every year.

Why a Likely Positive Surprise?

Our proven model shows that Perrigo Company is likely to beat earnings because it has the right combination of two key ingredients.

Positive Zacks ESP (Expected Surprise Prediction): This is because the Most Accurate estimate stands at $1.33 while the Zacks Consensus Estimate is lower at $1.32 per share. This results in a difference of +0.76%.

Zacks Rank #3 (Hold): Note that stocks with Zacks Rank of #1, #2 and #3 have a significantly higher chance of beating earnings. The sell rated stocks (#4 and #5) should never be considered while going into an earnings announcement.

The combination of Perrigo Company’s Zacks Rank # 3 (Hold) and +0.76% ESP causes us to expect a positive earnings beat on Feb 1, 2013.

What is Driving the Better Than Expected Earnings?

Perrigo Company is expected to deliver a positive earnings surprise in the second quarter of fiscal 2013 driven by increased revenues.

This healthcare company has delivered positive earnings surprises consecutively over the last 4 quarters with an average beat of 6.00%. The impressive performance over the last few quarters is attributable to solid revenues, primarily due to impressive sales at the generic (Rx Pharmaceuticals) segment of Perrigo.

Newly launched products have also boosted revenues at Perrigo over the last few quarters. During the first quarter fiscal 2013 conference call, the company announced its intention to launch more than 60 new products in fiscal 2013, which could generate revenues of more than $190 million. The company intends to launch more than 1 new product per week in fiscal 2013.

Earlier in the month, Perrigo announced that it has launched over-the-counter (OTC) nicotine polacrilex mini lozenge, 2 mg (mint flavor) and 4 mg (mint flavor). The mint flavored mini lozenge can be compared to GlaxoSmithKline's (GSK - Analyst Report) Nicorette mini lozenge.

Other Stocks to Consider

Perrigo Company, which develops, manufactures and distributes OTC and generic prescription pharmaceuticals among others, is not the only company looking up this earnings season. We also see likely earnings beat coming from other players in the generic market.

Mylan Inc (MYL - Analyst Report) has Earnings ESP of +4.69% and carries a Zacks Rank #2 (Buy).

Actavis Inc (ACT - Analyst Report) has Earnings ESP of +3.92% and carries a Zacks Rank #3 (Hold).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%